CARMEL, Ind., Jan. 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at, and participate in, the following upcoming investor conferences:
Guggenheim SMID Cap Biotechnology Conference
Date: Wednesday, February 5, 2025
Format: Fireside Chat
Time: 2:00 - 2:25 p.m. EST
Location: New York, NY
BIO CEO & Investor Conference
Date: Monday, February 10, 2025
Format: Panel Presentation
Time: 11:00 a.m. – 12:00 p.m. EST
Location: New York, NY
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual)
Date: Tuesday, February 11, 2025
Format: Podium Presentation
Time: 8:40 - 9:10 a.m. EST
Live webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Kate Burdick
Inizio Evoke Comms
This email address is being protected from spambots. You need JavaScript enabled to view it.
860-462-1569
Investor Contact:
Jim DeNike
MBX Biosciences
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.63 |
| Daily Change: | -0.76 -8.09 |
| Daily Volume: | 213,824 |
| Market Cap: | US$288.410M |
March 05, 2025 March 03, 2025 January 07, 2025 December 02, 2024 November 18, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
